Soyasaponin Ba

Soyasaponin Ba is a soyasaponin that can be isolated from Phaseolus vulgaris, acts as an aldose reductase inhibitor (ARI). Soyasaponin Ba activates Akt/GSK3β/β-catenin signaling pathway, reduces lipid accumulation, lowers ROS generation, improves mitochondrial membrane potential, ATP levels, and morphology, and inhibits apoptosis. Soyasaponin Ba can be used for the research of lipid accumulation and secondary diabetic complications^[1][2]. In Vitro:Soyasaponin Ba (0.78-25 μM; 0-600 s) directly binds to purified AKT1 protein with a K_d of 4.19 μM^[1].
Soyasaponin Ba (4-32 μM; 24 h) dose-dependently alleviates FFA-induced intracellular ROS accumulation, and improves FFA-induced mitochondrial dysfunction in HepG2 cells^[1].
Soyasaponin Ba (4-32 μM; 24 h) dose-dependently alleviates FFA-induced apoptosis in HepG2 cells^[1].
Soyasaponin Ba (16-32 μM; 24 h) activates the Akt/GSK3β/β-catenin signaling pathway in FFA-induced HepG2 cells^[1].
Soyasaponin Ba (8-32 μM; 24 h) dose-dependently alleviates FFA-induced lipid accumulation in THLE-2 cells^[1].
Soyasaponin Ba (16-32 μM; 24 h) dose-dependently alleviates FFA-induced ROS accumulation, mitochondrial dysfunction, and apoptosis in THLE-2 cells^[1]. In Vivo:Soyasaponin Ba (16-128 μM; incorporated into nematode growth medium; every 48 hours; 3-4 total doses; from L4 stage) dose-dependently alleviates high-glucose induced lipid accumulation and oxidative stress in wild-type N2 C. elegans^[1].